Cargando…

Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population

Background: Blood eosinophils may predict response to inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease (COPD) where ICS is recommended in patients at high risk of exacerbations. The proportion of patients who may benefit the most from ICS-based therapy was quantified in a real-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vestbo, Jørgen, Vogelmeier, Claus F, Small, Mark, Siddall, James, Fogel, Robert, Kostikas, Konstantinos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489586/ https://www.ncbi.nlm.nih.gov/pubmed/31114183 http://dx.doi.org/10.2147/COPD.S189585

Ejemplares similares

Evaluation of exacerbations and blood eosinophils in UK and US COPD populations
por: Vogelmeier, Claus F., et al.
Publicado: (2019)

Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study
por: Vogelmeier, Claus F, et al.
Publicado: (2018)

In ‘real world’ patients with COPD, exacerbation history, and not blood eosinophils, is the most reliable predictor of future exacerbations
por: Worth, Heinrich, et al.
Publicado: (2023)

Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids
por: Siddiqui, Salman H, et al.
Publicado: (2018)

“Real-life” inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD
por: Vogelmeier, Claus, et al.
Publicado: (2017)

Inhaled corticosteroids in COPD and onset of type 2 diabetes and osteoporosis: matched cohort study
por: Price, David B., et al.
Publicado: (2019)

Exacerbation Frequency And Eosinophil Counts Among Patients With COPD Currently Prescribed Triple Therapy
por: Benson, Victoria S, et al.
Publicado: (2019)

The sputum transcriptome better predicts COPD exacerbations after the withdrawal of inhaled corticosteroids than sputum eosinophils
por: Ditz, Benedikt, et al.
Publicado: (2021)

Change in inhaled corticosteroid treatment and COPD exacerbations: an analysis of real-world data from the KOLD/KOCOSS cohorts
por: Lee, Se Hee, et al.
Publicado: (2019)

Exacerbations of COPD
por: Viniol, Christian, et al.
Publicado: (2018)

COPD patients prescribed inhaled corticosteroid in primary care: time for re-assessment based on exacerbation rate and blood eosinophils?
por: Savran, Osman, et al.
Publicado: (2021)

Relationship Between Blood Eosinophils and Systemic Corticosteroid Therapy in COPD Exacerbation
por: Gong, Yaya, et al.
Publicado: (2022)

Blood eosinophilia, use of inhaled corticosteroids, and risk of COPD exacerbations and mortality
por: Oshagbemi, Olorunfemi A., et al.
Publicado: (2018)

Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study
por: Morjaria, Jaymin B., et al.
Publicado: (2017)

Effect of inhaled corticosteroids on blood eosinophil count in steroid-naïve patients with COPD
por: Kreindler, James L, et al.
Publicado: (2016)

Blood eosinophils and inhaled corticosteroids in patients with COPD: systematic review and meta-analysis
por: Cheng, Shih-Lung
Publicado: (2018)

Early Clinically Important Improvement (ECII) and Exacerbation Outcomes in COPD Patients
por: Kostikas, Konstantinos, et al.
Publicado: (2020)

Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study
por: Buhl, Roland, et al.
Publicado: (2018)

Prevention of COPD exacerbations: medications and other controversies
por: Vestbo, Jørgen, et al.
Publicado: (2015)

Elevated blood eosinophils in acute COPD exacerbations: better short- and long-term prognosis
por: Jabarkhil, Ajmal, et al.
Publicado: (2020)

Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD
por: Pavord, Ian D, et al.
Publicado: (2016)

The Association Between Eosinophil Variability Patterns and the Efficacy of Inhaled Corticosteroids in Stable COPD Patients
por: Yoon, Jung-Ki, et al.
Publicado: (2020)

Bronchiectasis-COPD Overlap Syndrome: Role of Peripheral Eosinophil Count and Inhaled Corticosteroid Treatment
por: Oscullo, Grace, et al.
Publicado: (2023)

Blood Eosinophils as Biomarkers to Drive Treatment Choices in Asthma and COPD
por: Kostikas, Konstantinos, et al.
Publicado: (2018)

The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD
por: Anzueto, Antonio R, et al.
Publicado: (2017)

Cardiovascular predictors of mortality and exacerbations in patients with COPD
por: Alter, Peter, et al.
Publicado: (2022)

Effectiveness using higher inhaled corticosteroid dosage in patients with COPD by different blood eosinophilic counts
por: Cheng, Shih-Lung, et al.
Publicado: (2016)

Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk
por: Brook, Robert D, et al.
Publicado: (2017)

A systematic evaluation of the diagnostic criteria for COPD and exacerbations used in randomised controlled trials on the management of COPD exacerbations
por: Mathioudakis, Alexander G., et al.
Publicado: (2019)

Inhaled Corticosteroids and the Lung Microbiome in COPD
por: Keir, Holly R., et al.
Publicado: (2021)

Treatment of COPD Groups GOLD A and B with Inhaled Corticosteroids in the COSYCONET Cohort – Determinants and Consequences
por: Lutter, Johanna I, et al.
Publicado: (2021)

"Show me the money": a fair criticism of economic studies on inhaled bronchodilators for COPD
por: Kostikas, Konstantinos, et al.
Publicado: (2010)

Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis
por: Harries, Timothy H., et al.
Publicado: (2020)

Mucolytics for acute exacerbations of chronic obstructive pulmonary disease: a meta-analysis
por: Papadopoulou, Efthymia, et al.
Publicado: (2023)

Shall We Focus on the Eosinophil to Guide Treatment with Systemic Corticosteroids during Acute Exacerbations of COPD?: PRO
por: Camp, James, et al.
Publicado: (2018)

Pulmonary biomarkers in COPD exacerbations: a systematic review
por: Koutsokera, Angela, et al.
Publicado: (2013)

Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO)
por: Rossi, Andrea, et al.
Publicado: (2014)

High eosinophil blood counts are associated with a shorter length of hospital stay in exacerbated COPD patients – a retrospective analysis
por: Greulich, Timm, et al.
Publicado: (2020)

Inhaled corticosteroid effects both eosinophilic and non-eosinophilic inflammation in asthmatic patients.
por: Basyigit, Ilknur, et al.
Publicado: (2004)

The association between eosinophilic exacerbation and eosinophilic levels in stable COPD
por: Kang, Hye Seon, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_27vegji9qnhffaaht8amhhj7ik